|
| 
|
|
|
|
 |
|
 |
|
|
|
 |
FEATURES |
 |
|
|
 |
Japan looks at emerging markets for growth
 |
|
| Regulatory hurdles, a difficult pricing and reimbursement environment, and the steady erosion of prices is likely to change Japaneses pharmaceutical market in near future |
|
|
|
|
|
|
|
|
 |
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TRENDS & ANALYSIS |
|
|
|
|
Battle against MRSA to net pharma industry US$2bn
|
|
| A number of new and expensive hospital brands targeting serious infections caused by multidrug-resistant bacteria, particularly Multidrug-resistant Staphylococcus aureus, will launch over the next decade, generating revenues totalling nearly $2bn |
|
|
|
|
|
Breast cancer cases on the rise in Japan
|
|
| The number of women diagnosed with breast cancer per year in the seven major markets is forecast to increase by 13 percent over the next decade, finds independent healthcare analyst, Datamonitor, whereas Japan will rise by approximately 24 percent |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
